Johnson & Johnson has announced the acquisition of precision immunology company Proteologix. The transaction is valued at USD 850 million in cash and potential additional milestone payments.
By entering the agreement with Johnson & Johnson, Proteologix aims to further develop its PX128 and PX130 programs, as well as antibody drugs in development targeted for treating severe atopic dermatitis (AD) and asthma. The acquisition also gives Johnson & Johnson access to other bispecific antibody programs with potential applications for various diseases.
Proteologix is a biotechnology company focused on developing therapeutics for immune-mediated diseases. The company leverages its proprietary multi-specific antibody technologies to target multiple disease pathways, aiming to increase efficacy and optimize dosages. The company’s lead candidates include PX128 and PX130, bispecific antibodies for moderate to severe AD and asthma.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.